Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia
- 1Ophthalmic Oncology Unit, Department of Ophthalmology, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia
- 2Institute of Medicine and Veterinary Science, Frome Road, Adelaide, SA 5000, Australia
- Correspondence to: Dr James Muecke Department of Ophthalmology, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia; raheyesmail.rah.sa.gov.au
- Accepted 5 April 2003
Abstract
Aim: To report the outcome of topical mitomycin C (MMC) used as adjunctive treatment following primary excision of ocular surface squamous neoplasia (OSSN).
Method: Prospective, non-comparative interventional case series of 27 primary OSSN lesions from 26 patients treated in a single ocular oncology centre over a 4 year period.
Result: 27 cases of OSSN received a treatment regimen of surgical excision, followed by topical MMC. Mean follow up of 27 (SD 12) months (range 12–50, median 25 months) revealed zero recurrences.
Conclusion: MMC treatment following surgical excision decreases the recurrence rate of primary ocular surface neoplasia and should be considered as adjunctive therapy in primary treatment.







